MENLO PARK, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq: CORI ), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Joseph J. Sarret, M.D., Chief Business Officer, will participate in a BioPharma Dealmakers webcast featuring five companies innovating drug delivery technology. The webcast, part of the BioPharma Dealmakers series of The Nature Publishing Group, is scheduled for 11:00 am EDT/8:00 am PDT on March 29th.
This webcast will highlight a range of diverse technologies and explain their applications in diseases such as oncology, CNS diseases and women’s health. Technologies covered within the webcast will include digitally controlled needle-free devices, sustained and controlled transdermal delivery technology, fiber-based technology for implantable devices, targeted penetration matrix technology for non-invasive delivery and location-specific nano machines for chemotherapy payload delivery.
The webcast will conclude with a live roundtable discussion and a Q&A section to allow the audience to ask questions directly.
Corium has a strong track record of developing complex transdermal products for partners and manufacturing them for clinical development and commercial sale. The company is now leveraging that expertise to build a high-value proprietary CNS pipeline, initially focused on Alzheimer’s disease, which can provide important benefits to patients and their families.
Dr. Sarret brings extensive US and international strategic business development and corporate transaction experience in the life science industry. Earlier in his career, he worked as a practicing clinician focused on patients with human immunodeficiency virus and as an attorney specializing in IP transactional work.
Joining Dr. Sarret on the webcast will be Dr. Patrick Anquetil, Chief Executive Officer of Portal Instruments Inc.; Dr. Kevin Nelson, Founder & Chief Scientific Officer of TissueGen Inc.; Dr. Paul Gavin, Chief Scientific Officer of Phosphagenics Limited; and Dr. Roy Farfara, Chief Scientific Officer of TrioxNano. The webcast will be moderated by Raveena Bhambra, Editor of BioPharma Dealmakers . Ms. Bhambra has worked in the biopharma industry for over 10 years specifically in the areas of dealmaking, partnering and licensing.
For more information and to register for the webcast, please access the BioPharma Dealmakers Webcast link here or by visiting the Investors section of Corium’s website at http://ir.coriumgroup.com/events.cfm . The webcast will be archived on the Corium website for two weeks following the presentation.
About the BioPharma Dealmakers Webcast
BioPharma Dealmakers webcasts are dedicated to small and large companies looking for commercial partnerships. Read the quarterly BioPharma Dealmakers supplement in Nature Biotechnology and Nature Reviews Drug Discovery .
About Corium
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor ® , a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics and additional transdermal products that are being developed with other partners. For further information, please visit www.coriumgroup.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our clinical trial and regulatory timing and plans, the achievement of clinical and commercial milestones, and the advancement of our technologies and our products and product candidates. Forward-looking statements are based on management's current expectations and projections and are subject to risks and uncertainties, which may cause Corium's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect Corium's business and its results are detailed in Corium's Quarterly Report on Form 10-Q for the quarter ended December 31, 2016, filed with the Securities and Exchange Commission on February 14, 2017, and other reports as filed from time to time with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial or operating performance, which speaks only as of the date they are made. Corium undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.
Corplex™ and MicroCor ® are trademarks of Corium International, Inc.
Source: Corium
Investor and Media Contact: SMP Communications Susan M. Pietropaolo susan@smpcommunications.com (201) 923-2049
